HPLC-UV and LC-MS/MS are the two principal analytical methods used in peptide quality control for research-grade compounds. Their application is complementary: HPLC-UV provides quantitative purity data based on UV absorption at the peptide bond; LC-MS/MS provides identity confirmation through molecular weight and fragmentation pattern. Neither method alone is sufficient for complete characterization — a CoA based solely on HPLC-UV purity cannot confirm sequence identity, and a mass spectrum without HPLC separation cannot quantify purity relative to UV-absorbing impurities.
HPLC-UV Method Parameters and Purity Calculation
Standard reverse-phase HPLC for peptide purity uses: C18 bonded-phase column (particle size 3–5 µm, column length 100–250 mm, internal diameter 2.1–4.6 mm); mobile phase A = 0.1% TFA in water or 0.1% formic acid in water; mobile phase B = 0.1% TFA in acetonitrile or 0.08% formic acid in acetonitrile; gradient: 5–95% B over 10–20 minutes, flow rate 0.3–1.0 mL/min; UV detection at 220 nm (amide bond n→π* transition, universal for peptides) with auxiliary detection at 254 or 280 nm if Trp/Tyr/Phe residues are present. Purity is calculated as: (main peak area / total integrated area) × 100%. This percentage refers to UV-absorbing material at 220 nm — it does not detect non-UV-absorbing impurities such as residual solvents, inorganic salts, or counterion species. For this reason, purity by HPLC-UV is a necessary but not sufficient quality specification when used alone.
LC-MS/MS for Identity Confirmation and Sequence Verification
Electrospray ionization mass spectrometry (ESI-MS) generates multiply-charged peptide ions in solution — typically [M+nH]n+ charge states, where n increases with peptide length and basicity. For a peptide of MW 1000 Da, expected ions include [M+H]+ at m/z 1001 and [M+2H]2+ at m/z 501.1. The average MW is confirmed by isotope deconvolution from the charge state envelope; high-resolution instruments (Orbitrap, Q-TOF) provide monoisotopic mass accuracy to <5 ppm, sufficient to distinguish single amino acid substitutions in short peptides. MS/MS fragmentation (CID or HCD) generates b- and y-ion series from which the sequence can be de novo assembled for peptides up to ~20 residues. For longer peptides, Edman degradation or proteolytic digest coupled LC-MS/MS is the definitive identity test. Related substances — des-amino derivatives, oxidized methionine, deamidated asparagine — appear as distinct peaks shifted by ±1, +16, or +1 Da respectively and are quantified by peak area in the chromatogram.
Related Substance Profiling: Common Impurity Identities
Research-grade peptide impurities typically fall into three categories:
- Truncation sequences: Failure sequences from SPPS (solid-phase peptide synthesis) — N-terminally truncated peptides lacking one or more N-terminal residues. Identified by MW deficit equal to the missing residue MW.
- Modification impurities: Oxidized Met (+16 Da), deamidated Asn/Gln (+1 Da), succinimide formation at Asp (-18 Da), acetylated N-terminus (+42 Da from incomplete deprotection). These are structurally characterized by MS/MS b/y-ion patterns.
- Racemization products: D-amino acid incorporation during SPPS — indistinguishable by standard MS but detectable by chiral HPLC. For stereochemically sensitive peptides, chiral QC should be specified.
Method Validation and CoA Reporting Requirements
For research-grade peptide QC methods to be scientifically defensible, HPLC-UV methods should be validated for: specificity (ability to separate main peak from related substances), linearity (R² ≥0.999 across expected concentration range), precision (RSD <2% for six replicate injections), and system suitability criteria (USP tailing factor <2.0, resolution >1.5 between main peak and nearest impurity). CoA reporting should include: column type and lot, mobile phase composition, gradient conditions, detector wavelength, injection volume, system suitability data, and the calculated purity percentage with individual impurity percentages ≥0.1%. Research compounds released without these data documented in the CoA are not fully characterized. These compounds are for research and laboratory use only. Not for unsupervised human consumption.